Ipca Laboratories Ltd
IPCALABIpca Laboratories Ltd's earnings have outrun its stock. EPS grew +54.7% in a year against a +29.2% price move.
The sharpest disagreement: annual EPS moved +54.7% against a +29.2% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (28 weeks in) while the P/E sits at the 53rd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +379.7% year on year, and 137% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Ipca Laboratories Ltd trades at ₹1,901, in a confirmed uptrend and 28 weeks into that stage. That is +24.0% against its own 200-day average. It sits at 100% of a 52-week range of ₹1,269 to ₹1,901. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 28 of stage 2, confirmed. At ₹1,901 it trades +24.0% versus its 200-day average and sits at 100% of its 52-week range (₹1,269–₹1,901).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +558% while the NIFTY 500 moved +272% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 53rd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Ipca Laboratories Ltd trades at 37.9× P/E, mid-range by its own standards (53rd percentile). Its long-run median P/E is 37.4×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 37.9× is mid-range by its own standards (53rd percentile), against a long-run median of 37.4× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +54.7% against a +29.2% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +12.6%/yr price move, ~+0.7%/yr came from earnings growth and ~+11.9 pp from the multiple (expanding); over 10y, of the +23.4%/yr price move, ~+29.5%/yr came from earnings growth and ~−6.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5,809% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Ipca Laboratories Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.0% and holding. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.9% | +15.7% | +12.2% | +12.8% |
| Profit | +50.8% | +35.2% | +0.7% | +29.0% |
| EPS | +54.7% | +34.3% | +0.0% | +28.4% |
| Share price | +29.2% | +34.9% | +12.6% | +23.4% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
65.2/100 — rank 6 of 43 in Pharma - Formulators · 79% evidence confidence
Ipca Laboratories Ltd scores 65.2 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 6. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 22.8 + 16.1 + 10.9 + 15.4 = 65.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Ipca Laboratories Ltd reported ₹2,388 Cr of revenue in the Mar 26 quarter, +6.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 12.8% a year. The last full year, FY26, came in at ₹9,599 Cr. The last four reported quarters add to ₹9,645 Cr.
Ipca Laboratories Ltd reported ₹2,388 Cr of revenue in the Mar 26 quarter, +6.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 12.8% a year. The last full year, FY26, came in at ₹9,599 Cr. The last four reported quarters add to ₹9,645 Cr.
FY26 revenue came in at ₹9,599 Cr (+7.9% on the year), capping 10 years at 12.8% compound. The latest quarter (Mar 26) printed ₹2,388 Cr, +6.3% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +7.9% growth against the decade's 12.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.9% over the last 4 quarters against +11.9%/yr over the last 8 — rolling over; TTM profit +51.0% vs +50.7%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 20.0% this quarter (+1.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Ipca Laboratories Ltd's operating margin is 20.0% in the Mar 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 29.0%. The current quarter sits inside that band.
Ipca Laboratories Ltd's operating margin is 20.0% in the Mar 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 29.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 20.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–29.0%.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went +2.6 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +379.7% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Ipca Laboratories Ltd earned ₹307 Cr of net profit in the Mar 26 quarter, +379.7% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹1,184 Cr. The 10-year compound rate is 29.0%. That is 12.9% of the quarter's revenue. The same quarter a year earlier earned ₹64.0 Cr.
Ipca Laboratories Ltd earned ₹307 Cr of net profit in the Mar 26 quarter, +379.7% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹1,184 Cr. The 10-year compound rate is 29.0%. That is 12.9% of the quarter's revenue. The same quarter a year earlier earned ₹64.0 Cr.
Mar 26 profit was ₹307 Cr, +379.7% year on year — the 8th consecutive quarter of growth. On the full year, FY26 printed ₹1,184 Cr (+50.8%), and the 10-year compound rate is 29.0%.
Why profit moved: revenue contributed +6.3% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +110.7% vs revenue +7.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 137% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 137% of Ipca Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,142 Cr of operating cash against ₹1,184 Cr of profit. After ₹929 Cr of capital spending, ₹213 Cr was left as free cash.
FY26: operating cash of ₹1,142 Cr against reported profit of ₹1,184 Cr, leaving free cash of ₹213 Cr after ₹929 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 137% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 137%: the cash cycle stretched 57 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹3,682 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Ipca Laboratories Ltd's cash conversion cycle runs 308 days in FY26, up from 251 days in FY21. Capital spending ran ₹3,682 Cr over the last 3 years. At FY26 sales of ₹9,599 Cr each day of that cycle holds about ₹26.3 Cr, so roughly ₹8,100 Cr sits inside the business at any moment.
FY26: debtors at 77 days, inventory at 353 days — roughly 11.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 308 days, looser than FY21's 251.
The full loop: cash goes out to suppliers and production on day 0; stock waits 353 days to sell; customers pay about 77 days after that; and suppliers themselves are paid at 122 days — netting out to the 308-day cycle.
In money terms: at FY26 sales of ₹9,599 Cr, each day of the cycle holds about ₹26.3 Cr — so the 308-day loop keeps roughly ₹8,100 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹3,682 Cr over the last 3 fiscal years against ₹1,173 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹773 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 17%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Ipca Laboratories Ltd earns a ROCE of 17% in FY26. That is up from a trough of 5% in FY16. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 12.3% net margin on 0.78× asset turns.
FY26 ROCE is 17%, recovered from a FY16 trough of 5% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.3% net margin × 0.78× asset turns × 1.53× balance-sheet leverage ≈ 14.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5,809% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.10.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Ipca Laboratories Ltd carries ₹809 Cr of borrowings against ₹8,063 Cr of equity in FY26, a debt-to-equity of 0.10. Operating profit covers the interest bill 25×. Over 5 years borrowings went from ₹265 Cr to ₹809 Cr. Capital spending ran ₹3,682 Cr across the last 3 of those years.
FY26: borrowings of ₹809 Cr against equity of ₹8,063 Cr — a debt-to-equity of 0.10. Operating profit covers the interest bill 25×. Over 5 years borrowings went from ₹265 Cr to ₹809 Cr while capital spending ran ₹3,682 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 5,809% on reported income across 15 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 3.6 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 3.6 points of Ipca Laboratories Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 37.0% of the company. Promoters moved −1.6 points over the same window, to 44.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +3.6 points over 8 quarters to 37.0%; Promoters: −1.6 points over 8 quarters to 44.7%; Foreign institutions: −0.1 points over 8 quarters to 10.7%.
Why the register moved: domestic institutions drove it (+3.6 points), absorbed on the other side by promoters (−1.6 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Ipca Laboratories Ltd: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
The safety line in one sentence: the Z-score is withheld — it comes from the second data source this page could not reconcile, and a solvency score is not worth printing on a number two sources dispute.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Ipca Laboratories Ltd this page | 37.9× | ₹44,720 Cr | Consistent | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Ipca Laboratories Ltd's share price today?
Ipca Laboratories Ltd trades at ₹1,901, +29.2% over the past year. The company is valued at ₹44,720 Cr. The stock sits at 100% of its 52-week range of ₹1,269–₹1,901, +24.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 28 weeks in. — as of 24 July 2026.
What were Ipca Laboratories Ltd's latest quarterly results?
Ipca Laboratories Ltd reported revenue of ₹2,388 Cr and net profit of ₹307 Cr for the Mar 26 quarter. Revenue rose 6.3% and profit rose 379.7% year on year. Earnings per share were ₹11.79. The operating margin was 20.0%, 1.0 pp higher than a year earlier. — as of 24 July 2026.
What is Ipca Laboratories Ltd's revenue?
Ipca Laboratories Ltd reported revenue of ₹2,388 Cr in the Mar 26 quarter, +6.3% year on year. For the full FY26 fiscal year, revenue was ₹9,599 Cr (+7.9%). Over the last 10 years revenue compounded at 12.8% a year. — as of 24 July 2026.
What is Ipca Laboratories Ltd's profit?
Ipca Laboratories Ltd earned ₹307 Cr of net profit in the Mar 26 quarter, +379.7% year on year — the 8th straight quarter of growth. Full-year FY26 profit was ₹1,184 Cr. The operating margin ran 20.0% in the latest quarter. — as of 24 July 2026.
What is Ipca Laboratories Ltd's market cap?
Ipca Laboratories Ltd's market capitalisation is ₹44,720 Cr at a share price of ₹1,901. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Ipca Laboratories Ltd's P/E ratio?
Ipca Laboratories Ltd trades at a P/E of 37.9×, at the 53rd percentile of its own 10-year range, against a long-run median of 37.4×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Ipca Laboratories Ltd pay a dividend?
Not in its latest year — Ipca Laboratories Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 11 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Ipca Laboratories Ltd overvalued?
On its own history, Ipca Laboratories Ltd looks mid-range against its own history: its P/E of 37.9× sits at the 53rd percentile of its 10-year range (long-run median 37.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Ipca Laboratories Ltd growing?
Yes — Ipca Laboratories Ltd is growing: latest-quarter revenue +6.3% year on year, profit +379.7%, and the margin +1.0 pp at 20.0%. The 10-year compound rates are 12.8% (revenue) and 29.0% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Ipca Laboratories Ltd performing?
Ipca Laboratories Ltd is in a confirmed uptrend, 28 weeks in. Its latest quarter's revenue rose 6.3% and profit rose 379.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Ipca Laboratories Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 17.0% and holding. The read comes from the last 12 quarters of growth (revenue growth +7.9% latest, profit growth +51.0% latest, eps growth +54.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Ipca Laboratories Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 28 of stage 2), trading +24.0% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Ipca Laboratories Ltd beating the market?
On recent form, yes — Ipca Laboratories Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +558% against the NIFTY 500's +272% — ahead of the index over the full window. — as of 24 July 2026.
Will Ipca Laboratories Ltd's share price go up?
This page publishes no price forecast for Ipca Laboratories Ltd. What it measures instead: the share price is ₹1,901, the price is in a confirmed uptrend 28 weeks in. Its P/E of 37.9× sits at the 53rd percentile of its own 10-year range. — as of 24 July 2026.
Who owns Ipca Laboratories Ltd?
Promoters hold 44.7% of Ipca Laboratories Ltd, foreign institutions 10.7%, domestic institutions 37.0% and the public 7.2% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 3.6 points over 8 quarters. — as of 24 July 2026.
Does Ipca Laboratories Ltd have too much debt?
No — Ipca Laboratories Ltd's debt-to-equity is 0.10, and operating profit covers the interest bill 25×. FY26 borrowings were ₹809 Cr against equity of ₹8,063 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Ipca Laboratories Ltd's capex?
Ipca Laboratories Ltd spent ₹3,682 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹929 Cr, with ₹773 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Ipca Laboratories Ltd's cash flow?
Ipca Laboratories Ltd generated ₹1,142 Cr of operating cash flow in FY26 and ₹213 Cr of free cash flow after ₹929 Cr of capital spending. Reported profit that year was ₹1,184 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Ipca Laboratories Ltd's profit real cash?
Yes — over the last 3 fiscal years, 137% of Ipca Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,142 Cr against reported profit of ₹1,184 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Ipca Laboratories Ltd in its business cycle?
Ipca Laboratories Ltd's FY26 operating margin was 21.0%, against a 13-year band of 10.0%–29.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Ipca Laboratories Ltd story?
The sharpest disagreement: annual EPS moved +54.7% against a +29.2% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Ipca Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Ipca Laboratories Ltd's earnings have outrun its stock. EPS grew +54.7% in a year against a +29.2% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.